Following Nelson, we aggregate data at the level of gene target-indication pair, the unit on which genetic evidence is computed. In total, we mapped 21934 gene target-indication pairs to a highest pipeline phase, in contrast to 8853 pairs labelled with a known phase in the Nelson et al. analysis. 5513 pairs could be tested for progression to a more advanced clinical phase since 2013, and 14759 pairs either absent or inactive in the 2013 data set could now be assigned a highest historical pipeline phase. Two validation sets (New Pipeline, and new GWAS associations) are larger than the original datasets used in Nelson et al. giving us sufficient power to test predictions.
